GREAT POINT PARTNERS LLC
Q2 2026 Form 13-F

GREENWICH, CONNECTICUT
CIK 0001281446 · CRD 158423 · SEC-registered investment adviser
Consolidated report · includes 2 managers since Q3 2013
$529.1M Reported Value Total

GREAT POINT PARTNERS, LLC reports 17 total accounts under management (AUM). There are 17 discretionary accounts valued at $1,777,101,406, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Firm Brochure (Part 2A)
Private funds (Form ADV)
38 funds · $2.0B gross asset value
Private Equity Fund: $1.4B · Hedge Fund: $564.4M
Source: Form ADV filed 2026-03-31
Reported value
$529.1M
Quarter over quarter
+16.1%
Holdings
37
Top-10 concentration
51.6%

Filing Structure

Reports holdings for

  • JAY JEFFREY R · File #028-12517 · since Q3 2013
  • Nordahl Lillian (not a 13F filer in our records) · File #028-24470 · since Q3 2024
  • Yehudai Ortav · File #028-20398 · Q3 2020 – Q2 2024
  • KROIN DAVID (not a 13F filer in our records) · File #028-13262 · Q3 2013 – Q2 2020

Holdings reported by

Key People

Form ADV owners & control persons
Jeffrey Robert Jay
ELECTED MANAGER, MEMBER AND MANAGING DIRECTOR
Adam Brian Felsenthal
GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER
Ronald Marc Panzier
CHIEF OPERATING OFFICER AND CHIEF FINANCIAL OFFICER
Q1 2026

Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.

Loading 13F Metrics

Q2 2026 13F filing summary

Period of report June 30, 2026
Filed August 14, 2026
Form 13F-HR
Reported value $529.1M
Positions 37
Change in reported value +21.6%
New positions 11
Exited positions 13
Position turnover 48.0%
Top-10 concentration 51.6%

13F filings by quarter

Quarter Positions Value
Q2 2026 13F
Filed Aug 14, 2026
 37 $529.1M
Q1 2026 13F
Filed May 15, 2026
 39 $435.1M
Q4 2025 13F
Filed Feb 17, 2026
 29 $308.4M
Q3 2025 13F
Filed Nov 14, 2025
 28 $242.5M
Q2 2025 13F
Filed Aug 14, 2025
 26 $153.8M
Q1 2025 13F
Filed May 15, 2025
 31 $188.8M
Q4 2024 13F
Filed Feb 14, 2025
 26 $212.2M
Q3 2024 13F
Filed Nov 13, 2024
 29 $339.8M
Q2 2024 13F
Filed Aug 14, 2024
 33 $522.0M
Q1 2024 13F
Filed May 15, 2024
 35 $641.6M
Q4 2023 13F
Filed Feb 14, 2024
 34 $586.7M
Q3 2023 13F
Filed Nov 14, 2023
 39 $549.0M
Q2 2023 13F
Filed Aug 14, 2023
 36 $510.8M
Q1 2023 13F
Filed May 15, 2023
 42 $509.3M
Q4 2022 13F
Filed Feb 14, 2023
 40 $510.2M
Q3 2022 13F
Filed Nov 14, 2022
 40 $415.3M
Q2 2022 13F
Filed Aug 15, 2022
 33 $417.0M
Q1 2022 13F
Filed May 16, 2022
 29 $413.8M
Q4 2021 13F
Filed Feb 14, 2022
 35 $450.1M
Q3 2021 13F
Filed Nov 15, 2021
 35 $429.5M

32 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q2 2026

# Holding Reported value % of portfolio
1 ABVX C ABIVAX SA $53.3M 10.07%
2 VOR VOR BIOPHARMA INC $31.3M 5.91%
3 ABVX ABIVAX SA $27.2M 5.15%
4 IBRX P IMMUNITYBIO INC $26.3M 4.97%
5 VERA VERA THERAPEUTICS INC $25.8M 4.87%
6 ZURA ZURA BIO LTD $24.9M 4.7%
7 ALMS ALUMIS INC $24.1M 4.55%
8 SLGL SOL-GEL TECHNOLOGIES LTD $20.3M 3.84%
9 RARE P ULTRAGENYX PHARMACEUTICAL IN $20.0M 3.79%
10 DFTX DEFINIUM THERAPEUTICS INC $20.0M 3.78%
11 ANNX ANNEXON INC $20.0M 3.78%
12 ORKA ORUKA THERAPEUTICS INC $17.4M 3.3%
13 MLTX MOONLAKE IMMUNOTHERAPEUTICS $16.7M 3.15%
14 SGMT SAGIMET BIOSCIENCES INC $15.7M 2.97%
15 CTNM CONTINEUM THERAPEUTICS INC $15.1M 2.85%
16 IMMX IMMIX BIOPHARMA INC $13.2M 2.49%
17 ELYM CLIMB BIO INC $13.0M 2.46%
18 AMLX AMYLYX PHARMACEUTICALS INC $12.6M 2.38%
19 NKTR NEKTAR THERAPEUTICS $12.2M 2.31%
20 NGNE NEUROGENE INC $11.1M 2.09%

Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.

Loading Activities
Loading Sector Allocation
Crunching numbers
Loading Performance
Finding Similar Managers
Finding Potential New Buys
Building table
Loading SEC filing data
Loading Form 4 Filings
Loading 13D/G filings